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Introduction
Despite recent improvements in neonatal care, the cen-
tral nervous system damage due to unconjugated biliru-
bin (UCB) is still being an important problem. Almost, all 
newborns demonstrate high serum UCB level, a form of 
hyperbilirubinaemia clinically called neonatal jaundice 
which is a benign and transient phenomenon. However, 
under certain conditions, UCB may induce adverse effects 
in the central nervous system because of the neurotoxic 
effect of hyperbilirubin1. Neurotoxicity of UCB is a vast 
clinical spectrum ranging from sensorineural hearing 
loss and choreoathetoid cerebral palsy, seizures or death 
from kernicterus, to mild mental retardation and subtle 
cognitive disturbance as mentioned bilirubin encepha-
lopathy2. Neurotoxicity caused by UCB includes more 
than one mechanism and most of these mechanisms are 
related with oxidative stress and apoptosis3–5. It is known 
that physiological or mildly increased concentrations 
of UCB have protective effects against oxidative stress6. 
However, moderate to severe hyperbilirubinaemia may 
lead to UCB deposition in the brain through a charac-
teristic pattern, with intense coloration of the basal gan-
glia, medulla oblangata and cerebellum (kernicterus)7. 
Nevertheless, there are still knowledge gaps regarding to 
neurologic features of UCB-induced brain injury5.
The neurons seem to be more susceptible than 
astrocytes to UCB-induced cell death by a mechanism that 
appears to involve oxidative stress3,4,8,9. Neural and glial 
cells are the main targets for UCB toxicity. UCB toxicity 
to neurons has been reported in brain sections, cultured 
cell lines, and isolated nerve terminals9. Recent studies 
have described that astrocyte functions are compromised 
following UCB exposure9–11. Astrocytes are glial cells that 
provide metabolic support to neurons and contribute to 
formation of the blood-brain barrier. Previous studies 
suggest that these cells are the main transporters of UCB 
from blood to neurons and are involved in the release 
of waste products from UCB-damaged neurons12,13. The 
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astrocytes may be the first cells that come into contact 
with UCB in blood-brain barrier failure. This raises the 
question of the sensitivity of astrocytes to UCB14.
The nervous system is highly enriched in long-
chain polyunsaturated fatty acids (LC-PUFAs). Fish 
and maternal milk are the major dietary sources of 
LC-PUFA such as docosahexaenoic acid (DHA)15,16. 
DHA, in particular, is the most abundant n-3 LC-PUFA 
in the brain and it is essential for the normal brain 
function17,18. Accretion of DHA in the central nervous 
system occurs actively during the developmental 
period19. While neurons are highly enriched with DHA, 
they cannot produce it because of lack of desaturase 
activity; only astrocytes have the capacity to synthesize 
DHA20. Astrocytes are in close contact with neurons 
and readily release DHA into the extracellular fluid 
under basal and stimulated conditions, thus providing 
a source for neuronal DHA21,22. Considering astroglia 
support neurons by providing neurotrophic factors, the 
supply of DHA by astrocytes can also be trophic23. DHA 
is an especially promising therapeutic or preventive 
intervention because it may simultaneously exert ben-
eficial effects on several of the injury cascades contrib-
uting to perinatal brain injury, including free radicals, 
inflammatory cytokines, bioactive lipid mediators, and 
apoptosis21,24–26. Berman et al. (2009) showed that DHA 
had neuroprotective and restorative effects in their ani-
mal models27. Although the role of DHA in bilirubin-
induced brain injury is unknown, DHA is known to 
have neuroprotective effects against oxidative stress 
and apoptosis. Therefore, this study was designed to 
evaluate the effects of DHA and UCB on astrocyte cell 




This study was approved by the Local Ethical Committee 
for Experimental Research at Pamukkale University. 
Astrocyte cell cultures were prepared from brains of 
1-day-old Wistar albino rat pups by a modification of the 
shake off method of Cole and de Vellis28,29. Briefly, after 
decapitation, brains were retrieved and meninges were 
completely trimmed. The brains were minced and dissoci-
ated mechanically and then sieved through a nylon mesh 
(pore size of 70 µm; Millipore). Cells were spin at 1500 
rpm/min for 5 min in a benchtop centrifuge, and the cell 
pellets were resuspended in Dulbecco’s Modified Eagle 
Medium/F12 (DMEM/F12) (DMEM/Ham’s F-12 1:1, 500 
mL, Biochrom, Berlin, Germany), containing 10% heat 
inactivated foetal bovine serum (FBS) (Hyclone, 100 mL, 
Thermo Scientific, Cromlington, UK), 500 µL gentamisin 
(Gentamisin, 10 mg/10 mL, Sigma-Aldrich, St Louis, 
USA) and 5 mL fungisone (Gibco Antibiotic–Antimycotic, 
25 µg/mL amphoterisin B, 100×/100 mL, Invitrogen, New 
York, USA). The resuspended cells were seed in 75-cm2 
flasks previously coated with 10 µg/mL of poly-d-lysine 
(PDL) (Sigma-Aldrich, St Louis, USA) for primary neuron 
cell cultures. Cells were incubated in a humidified CO
2
 
incubator at 37°C, CO
2
 5% and humidify 95% with changes 
of medium every 3 days. After 8–10 days of culture, macro-
phages and loosely attached cells were removed from the 
astrocyte monolayer by shaking cultures at 150 rpm for 1 
h. Then oligodendrocytes present on the top of a conflu-
ent monolayer of astrocytes were dislodged by shaking 
at 150 rpm for 24 h on orbital shaker. The medium con-
taining floating cells, microglias and oligodendrocytes 
were removed to different flasks. At the bottom of flasks, 
astrocyte cells were collected and the cell pellets were 
resuspended in astrocyte medium (DMEM/F12 contain-
ing 500 µL gentamisin, 5 mL fungisone, 15% FBS, 5 mL 
l-glutamine (Gibco l-Glutamine-200 mM, 100×/100 mL, 
Invitrogen, New York, USA)) and 500 µL insulin (Human 
Insulin <rh>, 0.5 mg/mL, Biochrom, Berlin, Germany). 
The method for the preparation of astrocytes has been 
estimated to yield cultures with purity approximating 
95% astrocytes and for experiments, these astrocyte cell 
cultures were used. Stock UCB solution was prepared in 
0.1 N NaOH and stored in the dark at 4°C until use. Stock 
UCB solution was further diluted with astrocyte medium 
under sterile conditions and added to cultures at various 
concentrations.
Determination of UCB and DHA concentrations and 
astrocyte cell viability
Cells were seeded in 96-well plates (3 × 104 cells/well). 
After 24 h, the cells treated with UCB the following con-
centrations: 1000 µM, 800 µM, 600 µM, 500 µM, 300 µM, 
200 µM, 100 µM, 80 µM, 60 µM, 50 µM, 30 µM, 20 µM, 10 
µM, 8 µM, 4 µM, 2 µM, 1 µM, 0.1 µM and 0.01 µM for 72 h. 
Astrocyte cells also treated with DHA with the following 
concentrations: 100 µM, 80 µM, 60 µM, 50 µM, 30 µM, 
20 µM, 15 µM, 8 µM, 6 µM, 5 µM, 3 µM, 1 µM and 0.1 µM 
to examine DHA toxic or not on cells. Absorbance (A), 
which was proportional to cell viability, was measured 
by luminometric method. Cell viability was measured 







 (72nd hour) and A
0
 (0th hour) are the 
absorbances obtained from treated cells and untreated 
cells, respectively.
Evaluation of apoptosis
Cells were treated with IC
50
 values of bilirubine before 
or after 4-h treatment of DHA to examine any protective 
effects. After 24 h incubation, cells were washed PBS 
and tripsinized. Deoxynucleotidyl transferase (TdT)-
mediated dUTP nick end labelling (TUNEL) method 
was used for determination of apoptosis. For TUNEL 
staining, ApopTag plus Peroxidase in Situ Apoptosis 
Detection (Millipore) kit was used in accordance with 
the manufacturer’s instructions. At least six random 
microscopic fields were counted per sample, and mean 
values were expressed as the percentage of apoptotic 
nuclei30.
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Evaluation of SOD, CAT and GPx enzyme activities
Cells were treated with IC
50
 values of UCB before or 
after 4-h treatment of DHA for examine any protective 
effects. After 24 h incubation, cells were washed PBS and 
tripsinized. And then we examined the effects of UCB 
and DHA on superoxide dismutase (SOD), CAT and GPx 
enzymes activity. SOD activity measurement method 
was based on the principle in which xanthine reacts with 
xanthine oxidase to generate superoxide radicals which 
react with tetrazolium salt to form a red formazon dye. 
The SOD activity is measured by the degree of inhibition 
of this reaction. For SOD activity measurement, SOD 
Assay Kit (Cayman) was used31.
Catalase activity was measured according to the 
method of Wheeler et al. 199032. The method is based on 
the reaction of the enzyme with methanol in the pres-
ence of an optimal concentration of hydrogen peroxide. 
For catalase activity measurement, catalase Assay Kit 
(Cayman) was used.
GPx activity was based on the method of Paglia and 
Valentine33. The principle of the method was as follows: 
GPx catalyses the oxidation of glutathione by cumene 
hydroperoxide. In the presence of glutathione reductase 
and NADPH, the oxidized glutathione is immediately 
converted to the reduced form with a concomitant oxida-
tion of NADPH to NADP+. The decrease in absorbance of 
NADPH was measured at 340 nm. For GPx activity mea-
surement, GPx Assay Kit (Cayman) was used.
Statistical evaluation
Statistical analyses were performed by Systat statistical 
software (version 17.0 for Windows; Statistical Packages 
for Social Sciences Inc, Chicago, IL, U.S.A.). The Kruskal−
Wallis and Mann−Whitney U test analysis were used 
for data analyses. Statistical significance was taken at 
p < 0.05. All data are presented as the mean ± SD.
Results
The astrocyte cell viability in the control group was con-
sidered to be 100% at 72nd hour, while the astrocyte cell 
viability percentage was found to be 11.5 ± 0.9, 13.9 ± 1.3, 
14.6 ± 1, 17.8 ± 0.5, 19.6 ± 0.3, 20 ± 1.07, 20.4 ± 0.85, 20.4 ± 
0.1, 27.5 ± 0.85, 30.1 ± 0.59, 35.4 ± 0.8, 46.4 ± 1.44, 51.6 ± 
1.8, 55.7 ± 1.6, 102 ± 2.08, 109.1 ± 0.85, 166.3 ± 1.8, 180.6 ± 
0.64 and 183.6 ± 0.8, in the 1000, 800, 600, 500, 300, 200, 
100, 80, 60, 50, 30, 20, 10, 8, 4, 2, 1, 0.1, and 0.01 µM UCB 
groups, respectively (Figure 1). IC
50 
of UCB for astrocyte 
cells was determined as 10 µM and this concentration 
was used in future experiments.
We also examined the effects of DHA on astrocyte cell 
viability. In Figure 2, it is clearly shown that astrocyte 
cell viability was increased after DHA treatment in all 
concentrations. Therefore, we can not calculate IC
50
 
values of DHA for astrocyte cells and the most effective 
concentration of DHA was determined as 5 µM and, 
then, this concentration was used in future experiments 
for examine the protective effects of DHA on astrocyte 
cells from UCB toxicity. Because we want to examine any 
protective effects of DHA on UCB toxicity in astrocyte 
cells, we pretreated cells for 4 h with DHA then add 
UCB (10 µM). Astrocyte cell viability was significantly 
decreased after 10 µM UCB treatment (51 ± 1.8%) when 
compared with untreated control group (p < 0.001). On 
the contrary, astrocyte cell viability was found to be 
significantly increased in the DHA pretreated cells (110 ± 
6.3%) (p < 0.001). After 72 h incubation, 10 µM UCB leads 
to the decrease of astrocyte cells viability, but only 4-h 
pretreatment of DHA enough for the terminate of UCB 
toxicity on astrocyte cells (Figure 3).
Because UCB has oxidant effects and DHA has anti-
oxidant ability we aim to examine the effects of UCB and 
DHA on SOD, CAT and GPx enzyme activities in astro-
cyte cells. Therefore, we incubated cells with 10 µM UCB, 
DHA 5 µM or preincubated DHA for 4 h then add UCB. 
After 24 h incubation, cells were washed PBS twice and 
then lysed. We used these lysates for determining of anti-
oxidant enzyme activity.
The SOD activity was found to be 0.24 ± 0.05 U/mg 
protein in the untreated control group, 0.22 ± 0.02 U/
mg protein in UCB treated cells, 0.42 ± 0.0007 U/mg 
protein in the DHA treated cells and 0.38 ± 0.02 U/mg 
protein in the pretreated DHA then UCB treated cells. 
Figure 1. Concentration-response curve of UCB. *p < 0.001 with 
respect to the control group.
Figure 2. Concentration-response curve of DHA. *p < 0.001 with 
respect to the control group.
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The SOD activity in the DHA treated cells were signifi-
cantly increased compared to the control (p < 0.001). 
Furthermore, 4-h pretreatment of DHA (5 µM) leads to 
the significantly increased SOD activity when compared 
with only UCB treated cells (p < 0.001) (Figure 4).
The catalase (CAT) activity was found to be 1.2 ± 
0.01 U/mg protein in the untreated control group, 0.22 
± 0.004 U/mg protein in the UCB treated cells, 5.75 ± 
0.002 U/mg protein in the DHA treated cells and 2.5 ± 
0.004 U/mg protein in the pretreated DHA then UCB 
treated cells. Although the CAT activity was significantly 
inhibit in the UCB treated cells, in only DHA treated or 
pre DHA then UCB treated cells, this CAT activity was 
significantly increased (p < 0.05). Furthermore, pretreat-
ment of DHA significantly terminate the negative effect 
of UCB on the catalase enzyme activity in astrocyte cells 
(p < 0.001) (Figure 5).
The glutathione peroxidase (GPx) activity was found 
to be 0.6 ± 0.015 U/mg protein in the untreated control 
group, 0.44 ± 0.010 U/mg protein in the UCB treated 
cells, 1.02 ± 0.011 U/mg protein in the DHA treated cells 
and 0.64 ± 0.011 U/mg protein in the pre DHA then 
UCB treated cells. Although the GPx activity was signifi-
cantly inhibited in the UCB treated cells compared with 
untreated control, DHA treated and pre DHA then UCB 
treated cells (p < 0.05) (Figure 6).
Because we observed that UCB has toxic effects on 
astrocyte cells and DHA can astrocyte protect cells from 
this UCB toxicity, we want to examine UCB toxicity 
come from induction of apoptosis or not and there 
is also any protective effects of DHA UCB mediated 
induction of apoptosis on astrocyte cells. Therefore, we 
treated astrocyte cells UCB (10 µM), DHA (5 µM) and 
4 h pretreated with DHA then UCB for 24 h. After the 
end of incubation time cell washed, and induction of 
apoptosis was determined with TUNEL assay. In Figure 7, 
it is clearly shown that UCB-induced apoptosis (25.27 ± 
2.1), and pretreatment of DHA leads to decrease of UCB-
induced apoptosis (10.9 ± 0.5) (p < 0.001). This means 
DHA has protective effects on UCB-induced apoptosis in 
astrocyte cells.
Discussion
UCB is a pigment resulting from the degradation of heme 
protein. Deposition of this pigment in the central ner-
vous system is the major factor causing UCB encepha-
lopathy during severe neonatal hyperbilirubinaemia34. 
The cytotoxic effect of UCB has been investigated mostly 
in neuronal and astroglial cells to date35. Although UCB 
is a well-known neurotoxin, the cellular mechanisms 
Figure 4. Evaluation of the SOD activity in the groups. *Decrease of 
the SOD activity in the group II compared to the groups I, III and IV 
(p < 0.05, p < 0.001 and p < 0.01, respectively). #Increase of the SOD 
activity in the group III compared to the group I, II and IV (p < 0.01, 
p < 0.001 and p < 0.05, respectively). $Increase of the SOD activity in 
the group IV compared to the group I and II (p < 0.01).
Figure 6. Evaluation of the GPx activity in the groups. *Decrease of 
the GPx activity in the group II compared to the group I, III and IV 
(p < 0.001). #Increase of the GPx activity in the group III compared 
to the group I, II and IV (p < 0.001). $Increase of the GPx activity in 
the group IV compared to the group I, and II (p < 0.01).
Figure 3. Alterations of the astrocyte cell viability in the groups (%). 
#Decrease of the cell viability of the group II compared to the group 
I, III and IV (p < 0.001). $Increase of the cell viability of the group III 
compared to the group I, II and IV (p < 0.001). &Increase of the cell 
viability of the group IV compared to the group I and II (p < 0.001).
Figure 5. Evaluation of the CAT activity in the groups. *Decrease 
of the CAT activity in the group II compared to the group I, III and 
IV (p < 0.05, p < 0.001 and p < 0.001, respectively). #Increase of the 
CAT activity in the group III compared to the group I, II and IV (p < 
0.001). $Increase of the CAT activity in the group IV compared to the 
group I and II (p < 0.001).
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mediating its toxicity remain poorly understood. It is 
hoped that clarification of toxicity mechanisms may yield 
novel ideas for future therapeutic approaches36. Various 
toxic effects to astrocyte cells involving the inhibition of 
DNA and protein synthesis, impairment of neurotrans-
mitter synthesis, release and uptake, inhibition of several 
mitochondrial enzymes and protein phosphorylation 
have been accounted for UCB neurotoxicity and most 
of these mechanisms are a result of oxidative stress11,34. 
The results of the present study are the first in vitro dem-
onstration on the astroglial cell culture that DHA has a 
protective effect against bilirubin neurotoxicity.
Moderate degrees of hyperbilirubinaemia turned 
out to be associated with a significant increase in minor 
neurologic dysfunction throughout the first year of life37. 
Neural and astrocyte cells are the main targets for UCB 
toxicity. Recent studies have shown toxic and apoptotic 
effects of UCB on astrocytes9,14. Tastekin et al. (2006) 
demonstrated that UCB was highly toxic in 10−3 M con-
centration, with cell death of about 90%36. Cell death was 
rather stable between 10−4 and 10−8 M concentration, 
causing cell death between 47 and 37%. In the present 
study, we demonstrated that UCB was highly toxic in 
10−3 M concentration, with cell death of about 90%. Even 
though high concentration of UCB increased cell death 
of astrocyte cells, low concentration of UCB (4−0.01 
µM) increases the astrocyte cell viability. These find-
ings supports the previous studies that UCB has a dual 
effect on astrocyte cells, being neuroprotective at lower 
concentrations, but neurotoxic at higher concentrations. 
Furthermore, the present study also demonstrated that 
IC
50
 of the UCB was 10 µM on astrocyte cells, as showed 
by Berns et al. (2009) and Tastekin et al. (2006)36,38.
Researchers have investigated the effects of fatty acids, 
especially DHA on several physiological systems for the 
past 25 years26,39. These includes heart disease, cancer, 
immune problems, neuronal functions, aging and “other” 
hard to categorize problems such as migraine headaches, 
malaria and sperm infertility40. Berman et al. (2009) have 
shown that DHA pretreatment provides effective neuro-
protection to the neonatal rat brain, improving functional 
testing to near-normal levels and reducing brain vol-
ume loss, particularly in the hippocampus, in perinatal 
hypoxia-ischemia animal model27. Furthermore, DHA is 
reported to play a neuroprotective role against oxidative 
stress in photoreceptors and to be important both for the 
maturation of retinal photoreceptors and for preventing 
photoreceptor apoptosis in the developing retina25,41,42. 
Shimazawa et al. (2009) also demonstrated that DHA had 
neuroprotective effects against oxidative stress in retinal 
ganglion cells26.
Several studies showed that DHA has protective 
effects in concentrations ranging between 2 and 6.7 µM. 
The higher concentrations than 10 µM were found to be 
causing photoreceptor cell death43. In the present study, 
it was found that no any concentration of DHA between 
0.1 and 100 µM had toxic effects on astrocyte cells.
Recently, many agents have been investigated in UCB 
neurotoxicity. Tastekin et al. (2006) have demonstrated 
that l-carnitine has neuroprotective effect against UCB 
neurotoxicity not also all concentrations but only 10−4 
M36. Zhang et al. (2010) showed that taurine pretreatment 
reduced UCB-mediated apoptotic cell death in primary 
neuron cultures in a concentration-dependent man-
ner1. Furthermore, minocycline, an anti-inflammatory 
and anti-apoptotic semisynthetic tetracycline has been 
shown that it prevents hyperbilirubinaemia-induced 
acute UCB neurotoxicity in jaundiced Gunn rat pups44. 
The present study showed that DHA increased astrocyte 
cells viability in all concentrations and had also a protec-
tive effect against UCB neurotoxicity.
Nerve cell injury induced by UCB has been suggested 
by two mechanisms: apoptosis and necrosis. Falcao et al. 
(2007) demonstrated that neurons which were exposed 
to UCB, dead by apoptosis5. Also in a recent study, the 
authors have provided evidence that low, clinically 
relevant concentrations of UCB promote delayed and 
programmed neuronal death reflecting an apoptotic 
phenomenon45. Moreover, Kumral et al. (2005) showed 
that UCB-induced cytotoxicity and apoptotic astrocyte 
death in a concentration and time dependent manner14. 
In this study, apoptosis was found to be 25% at 72nd hour 
in 10 µM UCB demonstrated for IC
50
. Hence, the present 
study also confirmed findings of previously studies.
The protective effects of DHA against apoptosis have 
been showed in vitro retinal photoreceptors studies25,42. 
Furthermore in these studies, the effectivity of DHA in 
therapeutic range has been reported between 2 and 6.7 
µM concentrations. Our results indicate that DHA had 
no any apoptotic effect and it has also protective effect 
against UCB-mediated apoptosis.
Although UCB was suggested a powerful antioxidant 
and a modulator of cell growth, recent studies have 
provided strong evidence in the last decade that, UCB 
neurotoxicity in part due to oxidative stress, which 
leads to DNA damage and cell growth reduction46. The 
organism’s defence system against oxidative stress 
and reactive oxygen species includes non-enzymatic 
mechanisms (vitamin A, E and C) and enzymes 
such as SOD, CAT and GPx47. Brito et al. (2004) have 
demonstrated that UCB induces oxidative stress 
Figure 7. Evaluation of apoptosis in the groups. *Apoptosis of the 
group II compared to the group I, III and IV (p < 0.001). **Apoptosis 
of the group IV compared to the group I and III and decrease of the 
apoptosis in the group IV compared to the group II (p < 0.001).
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in cortical synaptosomal membrane systems, by 
means of enhanced formation of free radical, protein 
oxidation and lipid peroxidation3. Also, in another 
study, authors have shown that UCB induces a dose-
dependent increase in neuronal death in parallel with 
the oxidation of cell components and a decrease in the 
intracellular glutathione content4. Bracci et al. (1988) 
showed that antioxidant enzymes of erythrocyte were 
significantly lower in cord blood and on the 4th day 
of life in babies with high bilirubinemia compared to 
less jaundiced babies48. Recently, Dani et al. (2003) 
have shown a decrease plasma bilirubin level and 
oxidative stress concominant with an increase in 
plasma antioxidant capacity in the preterm infants49. 
In the present study, here we show that UCB inhibits 
the SOD, CAT and GPx enzyme activities in the 
astrocyte cell culture compared to the untreated 
control group.
Hossain et al. (1999) have reported the antioxida-
tive effects of DHA in aged and hypercholesterolemic 
rats50. Authors have suggested that DHA may play an 
important role in antioxidative defence mechanism 
by enhancing the cerebral activities of CAT, GPx and 
glutathione. Afterward, many studies were reported 
that DHA increase the antioxidant enzyme activities 
including SOD, CAT and GPx in the different cell lines 
such as retinal ganglion cells, cerebellar astrocytes 
and neurons cells23,25,26. In an ischemia-reperfusion 
animal model study, Bas et al. (2007) have reported 
that DHA increases SOD activity in rat hippocam-
pus24. Additionally, Ozen et al. (2008) have shown 
the increased CAT activity on cerebral ischemia in rat 
prefrontal cortex by DHA pretreatment51. In another 
animal study, Choi-Kwon et al. (2004) have demon-
strated that the SOD, CAT, and GPx cerebral activi-
ties increased due to DHA treatment52. A recent study 
investigated the effects of n-3 polyunsaturated fatty 
acids in the prevention and treatment of neurological 
diseases, authors showed no any toxic effect of DHA 
in glial cells. Moreover, it was reported that low con-
centrations of DHA leads to increase GPx and CAT 
activities53. In the present study, we demonstrated 
that DHA not only significantly increased SOD, CAT 
and GPx activities in the astrocyte cell culture but also 
prevented to UCB-mediated inhibition of these anti-
oxidant enzymes activities.
In conclusion, we conclude that the neuroprotec-
tive effect of DHA against UCB neurotoxicity observed 
in this study is primarily because of the increasing the 
cell viability and the antioxidant enzyme activities of 
SOD, CAT and GPx and the inhibition of apoptosis. 
To our knowledge, this study is the first to demon-
strate the neuroprotective effects of DHA against UCB 
neurotoxicity. Further research is needed to confirm 
our findings and to clarify the future mechanisms 
responsible for the protective effects of DHA on UCB 
neurotoxicity.
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